Xencor, Inc.

XNCR ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2017 FY2016
Revenue $46.2M $109.0M
Cost of Revenue — —
Gross Profit — —
Gross Margin — —
Operating Expenses
Research & Development $71.8M $51.9M
SG&A Expense $17.5M $13.1M
Operating Income $-43.1M $44.0M
Operating Margin -93.4% 40.4%
Interest Expense $13.0K $21.0K
Pretax Income $-38.9M $46.1M
Income Tax Expense $-463.0K $991.0K
Net Income $-38.5M $45.1M
Net Margin -83.4% 41.4%
EPS (Basic) $-0.82 $1.09
EPS (Diluted) $-0.82 $1.07
Shares Outstanding (Basic) 46.8M 41.3M
Shares Outstanding (Diluted) 46.8M 42.4M
Dividends Per Share — —
← Newer Page 2 of 2 Older →